| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 1 项专利证书，具体情况如下： 发明专利摘要： 本发明涉及偶联物在制备检测试剂中的用途。具体而言，本发明的 6-磷酸 葡萄糖脱氢酶突变体相较于野生型 6-磷酸葡萄糖脱氢酶包含选自以下的一个突 变或其组合：D306C、D375C、G426C。使用本发明的 6-磷酸葡萄糖脱氢酶突变体 所制备的检测试剂盒，其特异性强、灵敏度高、操作方便、检测时间短、定量准 确，适合高通量检测。 二、对公司的影响 上述发明专利证书的取得不会对公司近期生产经营产生重大影响，但有利于 发挥公司的知识产权优势，促进技术创新，提升公司的核心竞争力，并形成持续 创新机制。 特此公告。 北京九强生 ...

Core Viewpoint - The company Jiukang Bio is experiencing a decline in stock price and financial performance, with a significant drop in revenue and net profit compared to the previous year, while its valuation remains low compared to the industry average [1][2]. Company Summary - Jiukang Bio's closing stock price on August 14 was 14.91 yuan, down 2.55%, with a rolling PE ratio of 17.65 times and a total market capitalization of 8.742 billion yuan [1]. - The company operates in the medical device industry, focusing on biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1]. - Jiukang Bio's main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, and laboratory auxiliary services [1]. - The company was recognized as a "National Enterprise Technology Center" on February 22, 2023, as part of the 29th batch of newly recognized national enterprise technology centers [1]. Financial Performance - In the first quarter of 2025, Jiukang Bio reported operating revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]. Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Jiukang Bio at 38th place within the industry [1][2]. - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation [2].

Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

金融界消息 截至2025年8月14日收盘，九强生物（300406）报收于14.91元，下跌2.55%，换手率 1.93%，成交量8.18万手，成交金额1.23亿元。 资金流向方面，今日主力资金净流出1064.13万元，占比成交额8.64%。其中，超大单净流出924.80万 元、占成交额7.51%，大单净流出139.34万元、占成交额1.13%，中单净流出流入856.99万元、占成交额 6.96%，小单净流入207.14万元、占成交额1.68%。 九强生物最新一期业绩显示，截至2025一季报，公司营业总收入3.20亿元、同比减少18.81%，归属净利 润8325.75万元，同比减少30.99%，扣非净利润8232.21万元，同比减少32.02%，流动比率10.570、速动 比率9.623、资产负债率25.16%。 天眼查商业履历信息显示，北京九强生物技术股份有限公司，成立于2001年，位于北京市，是一家以从 事研究和试验发展为主的企业。企业注册资本58630.8628万人民币，实缴资本24983.7313万人民币。公 司法定代表人为邹左军。 通过天眼查大数据分析，北京九强生物技术股份有限公司共对外投资了8家企业 ...

公告显示，补体C1q测定试剂盒(胶乳免疫比浊法)用于体外定量测定人血清或血浆样本中补体C1q的含 量。基质金属蛋白酶—3测定试剂盒(胶乳免疫比浊法)用于体外定量测定人血清或血浆中基质金属蛋白 酶—3(MMP—3)的含量。 北京商报讯(记者王寅浩实习记者宋雨盈)8月14日，九强生物（300406）发布公告称，公司产品补体C1q 测定试剂盒(胶乳免疫比浊法)和基质金属蛋白酶—3测定试剂盒(胶乳免疫比浊法)取得北京市药品监督管 理局颁发的《医疗器械注册证》。 ...

Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for products including the "Complement C1q Detection Kit" [2] Company Summary - Jiukang Bio (SZ 300406, closing price: 14.91 yuan) announced on August 14 that it has obtained a medical device registration certificate [2] - The company's revenue composition for the year 2024 is projected to be 100.0% from the healthcare sector [2]

九强生物8月14日公告，公司补体C1q 测定试剂盒（胶乳免疫比浊法）、基质金属蛋白酶-3 测定试剂盒 （胶乳免疫比浊法）获得北京市药品监督管理局颁发的医疗器械注册证。取得医疗器械注册证丰富了公 司产品类别，有利于增强公司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响。 ...

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-057 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | | 注册 类别 | | | 注册证有效期 | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 补体 C1q 测定试剂 盒（胶乳免疫比浊 | 京 械 注 | 准 | Ⅱ | | | 自批准之日起有效期 | | | 本试剂盒用于体外定量 测定人血清或血浆样本 | | | 法） | 20252400248 | | | 至 2030 | 年 | 07 | 月 | 30 日 | 中补体 C1q 的含量。 | | 2 | 基质金属蛋白酶-3 | 京 械 注 | 准 | | | | 自批准之日起有效期 | | | 本试剂盒用于体外定量 测定人血清或血浆中基 | | | 测定试 ...

（文章来源：证券日报） 证券日报网讯 8月12日晚间，九强生物发布公告称，公司近日收到北京市药品监督管理局颁发的《医疗 器械注册证》，产品名称为免疫球蛋白A测定试剂盒（胶乳免疫比浊法）。 ...

九强生物（SZ 300406，收盘价：15.14元）8月12日晚间发布公告称，北京九强生物技术股份有限公司 于近日收到北京市药品监督管理局颁发的《医疗器械注册证》。产品名称为"免疫球蛋白A测定试剂 盒"。 2024年1至12月份，九强生物的营业收入构成为：医疗卫生占比100.0%。 （文章来源：每日经济新闻） ...